TC
KIN

TFS Capital’s Kindred Biosciences, Inc. KIN Stock Holding History

TFS Capital’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-36,157
Closed -$311K – 459
2017
Q2 		$311K Buy
36,157
+8,513
+31% +$61.1K 0.12% 338
2017
Q1 		$195K Sell
27,644
-783
-3% -$4.91K 0.06% 496
2016
Q4 		$121K Buy
+28,427
New +$138K 0.03% 615
2015
Q1 		– Sell
-20,453
Closed -$152K – 1194
2014
Q4 		$152K Sell
20,453
-16,957
-45% -$144K 0.01% 864
2014
Q3 		$346K Buy
37,410
+22,851
+157% +$309K 0.03% 711
2014
Q2 		$271K Buy
14,559
+3,565
+32% +$60.6K 0.02% 863
2014
Q1 		$204K Buy
+10,994
New +$210K 0.01% 1182

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TFS Capital's KIN Position: Q3 2017 in Review

TFS Capital sold out of Kindred Biosciences, Inc. (KIN) in Q3 2017, closing a stake of 36,157 shares — an estimated $311K sold.

TFS Capital first reported a position in KIN in Q1 2014 and held it in 7 quarters. The position peaked at $346K in Q3 2014. 67 funds tracked by Wall St. Rank hold KIN as of Q3 2017.

  • TFS Capital reported no remaining Kindred Biosciences, Inc. position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 36,157 Kindred Biosciences, Inc. shares in Q3 2017, an estimated $311K.
  • TFS Capital first reported a position in Kindred Biosciences, Inc. in Q1 2014 and held it in 7 quarters.
  • TFS Capital's Kindred Biosciences, Inc. position peaked at $346K in Q3 2014.
  • 67 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.